Editas (EDIT) Focuses On Developing Eye Candidate EDIT-101
Zacks Investment Research | Jul 05, 2019 08:57AM ET
On Jul 3, we initiated a research report on Editas Medicine, Inc. (NASDAQ:EDIT) .
The company’s lead pipeline candidate, EDIT-101, which uses CRISPR gene editing, is being developed for treating Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness.
Editas is developing EDIT-101 in partnership with Allergan (NYSE:AGN) . The company has a strategic alliance and option agreement with Allergan under which, the latter reserves rights to in-license up to five of Editas’ genome editing ocular programs. Last July, Allergan exercised its option to develop and commercialize EDIT-101 globally while Editas exercised its right to a profit-sharing understanding with Allergan under which, the company will co-develop and equally divide the profits and losses from EDIT-101 in the United States.
Both companies plan to begin patient dosing in the phase I/II dose escalation study on EDIT-101 during the second half of 2019.
The company is also pursuing the development of CRISPR candidates for eye diseases other than LCA10, which include Usher Syndrome type 2A (USH2A) and the recurrent ocular Herpes Simplex Virus type 1 (HSV-1).
Last month, Editas commenced investigational new drug (IND) enabling activities for EDIT-301, an experimental CRISPR medicine, designed to treat sickle cell disease and beta-thalassemia by editing the beta-globin locus.
By the end of 2022, Editas targets to have three medicines in early-stage clinical development and at least two in or ready for late-stage studies.
Shares of Editas have gained 8% so far this year, underperforming the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.